Biopharma News

Sep 14, 2017
By BioPharm International Editors
Shingrix represents a new, possibly better alternative to existing treatments.
Sep 14, 2017
By BioPharm International Editors
Focused around Purdue University’s LyoHUB, a new blueprint aims to bring innovation to equipment and processes. One goal? Continuous freeze drying.
Sep 12, 2017
By BioPharm International Editors
Alexion’s restructuring will reduce its global workforce by 20%, including closing a manufacturing facility in Rhode Island.
Sep 11, 2017
By BioPharm International Editors
J&J’s Janssen ends a 2015 collaboration with Achillion Pharmaceuticals with a strategic decision to discontinue further development of a hepatitis C therapy in favor of pursuing hepatitis B therapeutics.
Sep 08, 2017
By BioPharm International Editors
The pharma major anticipates an annualized cost savings of roughly $500 million starting in 2018 based on a significant reduction in its global workforce.
Sep 07, 2017
By BioPharm International Editors
Roche’s subsidiary, Genentech, issued the voluntary recall of the anti-stroke drug because of compromised vials containing sterile water that were packaged with the drug.
Sep 07, 2017
By BioPharm International Editors
With this acquisition, Merck gains a lead anti-tumor drug candidate and a proprietary technology that can potentially induce immediate and long-term anti-tumor immunity.
Sep 07, 2017
By BioPharm International Editors
Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.
Sep 07, 2017
By BioPharm International Editors
As Merck KGaA continues its strategic shift into a science and technology company, it is considering options for its Consumer Health business, including a potential sale.
Sep 06, 2017
By BioPharm International Editors
Pfizer’s Mylotarg, an anti-body drug conjugate once voluntarily withdrawn, returns to the market under a new dosing regimen for treating leukemia.
native1_300x100
lorem ipsum